Table 1.

Univariate analysis of risk factors associated with treatment delay in TBM patients

	Short delay	Long delay	Total	P value
N	84	77	161
Age (years)	28.3 ± 16.9	34.1 ± 17.2	31.1 ± 17.2	0.037
Sex (male)	48	40	88	0.509
Time during hospitalization (days)	56.6 ± 44.6	64.6 ± 47.1	60.4 ± 45.9	0.273
Fees ($)	78,721 ± 71,922	98,186 ± 108,770	88,030 ± 91,645	0.192
Previous anti-TB therapy	5	14	19	0.022
Smoking habit (pack-years)	2.82 ± 9.10	3.36 ± 11.9	3.08 ± 10.50	0.746
Contact history of TB	10	8	18	0.761
No. of Healthcare visits	2.3 ± 0.9	2.8 ± 1.3	2.5 ± 1.1	0.010
Comorbidity
Pulmonary TB	54	55	109	0.334
Extrapulmonary TB	23	25	48	0.481
Rheumatic diseases	3	5	8	0.401
Diabetes mellinus	3	8	11	0.434
Milliary TB	22	29	51	0.120
Recurrent TB	3	9	12	0.064
Symptoms
Fever	68	48	116	0.010
Headache	63	27	90	0.000
Vomitting	23	8	31	0.008
Cough	10	20	30	0.025
Hydrocephalus	13	5	18	0.147
Abnormalty in brain CT	37	27	64	0.941
CSF examination
WBC (109/L)	207 ± 210	187 ± 183	198 ± 198	0.524
Mononuclear cells (%)	64 ± 28	54 ± 28	59 ± 29	0.041
Polynuclear cells (%)	36 ± 29	46 ± 28	41 ± 28	0.037
Glucose (mmol/L)	1.96 ± 1.21	2.26 ± 1.81	2.11 ± 1.53	0.223
Tryptophan (+)	59	49	108	0.708
Lactate (mmol/L)	6.75 ± 2.37	6.40 ± 2.43	6.58 ± 2.39	0.410
AST (U/L)	18.7 ± 16.5	17.8 ± 10.5	18.3 ± 13.9	0.671
LDH (U/L)	136 ± 209	120 ± 138	129 ± 178	0.569
CSF-PR (mg/L)	1323 ± 649	1456 ± 758	1387 ± 704	0.230
α-HBDH (U/L)	131 ± 402	70 ± 73	102 ± 296	0.257
Chloride (mmol/L)	108 ± 8	111 ± 8	109 ± 8	0.038
ADA (U/L)	8.1 ± 8.1	8.5 ± 6.4	8.3 ± 7.3	0.738
CSF/Serum glucose	0.32 ± 0.18	0.32 ± 0.18	0.32 ± 0.18	0.932
Serum glucose (mmol/L)	6.30 ± 1.54	7.07 ± 3.27	6.66 ± 2.53	0.084